A Tool to Predict Tuberculosis Drug Resistance Now Available Online
|
By LabMedica International staff writers Posted on 09 Jun 2015 |
|
![Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2015-06-09/GMS-170.jpg "Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).")
Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
A new online tool for the rapid analysis of whole genome sequence data is set to aid clinicians predict whether a particular patient's tuberculosis (TB) will be susceptible to frequently prescribed antibiotics.
The World Health Organization (WHO) estimated that 5% of the world's 11 million tuberculosis patients have multi-drug-resistance disease (MDR-TB) and that 480,000 new cases arose during 2013 alone. Of those approximately 9% have extensively resistant tuberculosis (XDR-TB) where, in addition to resistance to at least both of the major first line drugs (isoniazid and rifampicin), they also have resistance to two classes of second line drugs used to treat MDR-TB (the fluoroquinolones and the injectable drugs, amikacin, kanamycin, or capreomycin).
Current molecular tests examine limited numbers of mutations in Mycobacterium tuberculosis, the organism that causes TB, and although whole genome sequencing could fully characterize drug resistance, the complexity of data obtained by this technology has restricted their clinical application.
To help solve this problem investigators at the London School of Hygiene & Tropical Medicine (United Kingdom) have created an online tool that analyses and interprets genome sequence data to predict resistance to 11 drugs used for the treatment of TB. Initially, a library (1,325 mutations) predictive of drug resistance for 15 anti-tuberculosis drugs was compiled and then validated for 11 of them using genomic-phenotypic data from 792 strains. A rapid online "TB-Profiler" tool was developed to report drug resistance and strain-type profiles directly from raw sequences. The TB-Profiler tool is available on the Internet (Please see Related Links below).
Senior author Dr. Taane Clark, reader in genetic epidemiology and statistical genomics at the London School of Hygiene & Tropical Medicine, said, "Sequencing already assists patient management for a number of conditions such as HIV, but now that it is possible to sequence M. tuberculosis from sputum from suspected multi-drug resistance patients means it has a role in the management of tuberculosis. We have developed a prototype to guide treatment of patients with drug resistant disease, where personalized medicine and treatment offers improved rates of cure."
Complete information regarding the new online tool was published in the May 27, 2015, online edition of the journal Genome Medicine.
Related Links:
TB-Profiler tool
London School of Hygiene & Tropical Medicine
The World Health Organization (WHO) estimated that 5% of the world's 11 million tuberculosis patients have multi-drug-resistance disease (MDR-TB) and that 480,000 new cases arose during 2013 alone. Of those approximately 9% have extensively resistant tuberculosis (XDR-TB) where, in addition to resistance to at least both of the major first line drugs (isoniazid and rifampicin), they also have resistance to two classes of second line drugs used to treat MDR-TB (the fluoroquinolones and the injectable drugs, amikacin, kanamycin, or capreomycin).
Current molecular tests examine limited numbers of mutations in Mycobacterium tuberculosis, the organism that causes TB, and although whole genome sequencing could fully characterize drug resistance, the complexity of data obtained by this technology has restricted their clinical application.
To help solve this problem investigators at the London School of Hygiene & Tropical Medicine (United Kingdom) have created an online tool that analyses and interprets genome sequence data to predict resistance to 11 drugs used for the treatment of TB. Initially, a library (1,325 mutations) predictive of drug resistance for 15 anti-tuberculosis drugs was compiled and then validated for 11 of them using genomic-phenotypic data from 792 strains. A rapid online "TB-Profiler" tool was developed to report drug resistance and strain-type profiles directly from raw sequences. The TB-Profiler tool is available on the Internet (Please see Related Links below).
Senior author Dr. Taane Clark, reader in genetic epidemiology and statistical genomics at the London School of Hygiene & Tropical Medicine, said, "Sequencing already assists patient management for a number of conditions such as HIV, but now that it is possible to sequence M. tuberculosis from sputum from suspected multi-drug resistance patients means it has a role in the management of tuberculosis. We have developed a prototype to guide treatment of patients with drug resistant disease, where personalized medicine and treatment offers improved rates of cure."
Complete information regarding the new online tool was published in the May 27, 2015, online edition of the journal Genome Medicine.
Related Links:
TB-Profiler tool
London School of Hygiene & Tropical Medicine
Gold Member
Hematology Analyzer
Medonic M32B
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Latest Microbiology News
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
Channels
Clinical Chemistry
view channel
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read more
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read more
Molecular Diagnostics
view channel
DNA Aptamers Offer New Tool for Easy Alzheimer's Blood Test
Alzheimer’s disease is the most common cause of dementia and is marked by progressive loss of nerve cells that begins many years before symptoms become noticeable. Detecting early signs of neurodegeneration... Read more
Jumping "DNA Parasites” Linked to Early Tumor Development
Cancer genomes accumulate complex structural variants that can be difficult to resolve with standard short-read sequencing, obscuring clinically relevant drivers of disease. Transposable elements, particularly... Read more
AI-Based Liquid Biopsy Detects Liver Fibrosis, Cirrhosis and Chronic Disease Signals
Liver fibrosis and cirrhosis often develop silently for years before symptoms appear, making early diagnosis difficult. Detecting these conditions earlier could allow treatment before irreversible damage... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read more
Technology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read more
Industry
view channel
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
